We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Method Identifies Fat Malabsorption

By LabMedica International staff writers
Posted on 11 Sep 2014
A novel clinical test known as the Serum Retinyl Palmitate Test (RP) has been assessed and validated for the diagnosis of fat malabsorption, and compared to the fecal fat test (FFT).

The differential diagnosis for malabsorptive diarrhea is broad, encompassing luminal, mucosal and lymphatic disorders involving different organ systems and the possibility of undiagnosed systemic endocrine or immunodeficient diseases also highlights the importance of a thorough work-up.

Image: The Series 1200 high pressure liquid chromatography (HPLC) system (Photo courtesy of Agilent Technologies).
Image: The Series 1200 high pressure liquid chromatography (HPLC) system (Photo courtesy of Agilent Technologies).

Clinical biochemists at the University of Calgary (AB, Canada) carried out a case-control study on patients identified with chronic diarrhea, defined as persistent symptoms for greater than four weeks, and suspected malabsorption. Healthy control subjects were also recruited. Blood samples were collected at intervals after the administration of oil-soluble vitamin A. A fecal fat test was conducted on samples of patients after the consumption of 100 grams of a fat diet. Patients were defined as malabsorbers if the 72-hour stool fat excretion was greater than 5.9 g/day.

Serum levels of retinol (vitamin A) and RP were measured by reversed-phase high pressure liquid chromatography (HPLC; Waters; Milford, MA, USA). The detection limit for retinol was 0.18 mg/L and for retinyl-palmitate, it was 0.02 mg/L. Sixteen patients completed this study, 8 cases and 8 control subjects. Fecal fat results were available for 15/16 patients. The sensitivity of the FFT was 100%, but the FFT specificity was 42%, as 4/7 control patients were identified as malabsorbers. Cases with short bowel syndrome (SBS) had the lowest RP levels, but this did not meet statistical significance. There was no significant difference for serum RP levels when comparing cases and control patients.

The authors concluded that the RP test did identify patients with severe malabsorption secondary to SBS, but the performance of the RP test in patients with malabsorption from non-SBS etiologies was poor. However, the so-called gold standard, 72-hour FFT, had poor performance characteristics, highlighting the need for more useful diagnostics in identifying malabsorption. The study was published on August 8, 2014, in the journal Clinica Chimica Acta.

Related Links:

University of Calgary 
Waters 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Platelet Function Analyzer
PL-12
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood

Latest Clinical Chem. News

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
10 Sep 2014  |   Clinical Chem.

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care
10 Sep 2014  |   Clinical Chem.

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
10 Sep 2014  |   Clinical Chem.